Brief: Aim Immunotech Enrolls And Doses First Subject In Phase 2 Study Evaluating Ampligen® For The Treatment Of Post-Covid Conditions
10/07/2023 13:47
AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ENROLLS AND DOSES FIRST SUBJECT IN PHASE 2
STUDY
EVALUATING AMPLIGEN® FOR THE TREATMENT OF POST-COVID CONDITIONS
* AIM IMMUNOTECH INC - ENROLLMENT EXPECTED TO BE COMPLETED
IN Q4
2023
Source text for Eikon: ID:nGNE6wlVLh
Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential